All In Biotech

Drug Trial Radar · NCT03272165

Single Ascending Dose Study of MEDI1341 in Healthy Volunteers

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in Healthy Male and Female Volunteers

Last checked: Nov 19, 2026Latest source record: Jun 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Oct 17, 2017

Primary completion

Mar 31, 2021

Study completion Mar 31, 2021

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Covance; MMS Holdings, Inc; Catalent; Takeda
First posted
Sep 5, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a study of single ascending intravenous doses of MEDI1341 or placebo in up to 48 healthy volunteers, aged 18 to 65 years. The study will include up to 6 planned cohorts; each cohort will comprise 8 participants. Each participant will receive a single 60 minute intravenous infusion of MEDI1341 or placebo and will undergo scheduled assessments over a period of 13 weeks. The main aim of the study is to assess the safety and tolerability of single doses of MEDI1341 in healthy volunteers.

Conditions

  • Parkinson's Disease

Interventions

  • MEDI1341Drug

    Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.

  • PlaceboDrug

    Participants will receive IV infusion of placebo matched to MEDI1341.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: Day 1 through 92 days after a single dose of study drug
  2. Number of Participants With Abnormal Vital Signs, Physical and Neurological Examinations, and Body Weight Measurements Reported as TEAEsTime frame: Day 1 through 92 days after a single dose of study drug
  3. Change from Baseline in 12-Lead Electrocardiogram (ECG) Data in Paper and Digital Recordings (PR Interval, QRS Duration, QT Interval, QTcF Interval, and RR Interval)Time frame: 12-lead paper ECG: Baseline (Day -49) to Day 92; Digital ECG: Baseline (Day 1) to Day 92
  4. Change from Baseline in Heart Rate by 12-Lead ECG in Paper and Digital RecordingsTime frame: 12-lead paper ECG: Baseline (Day -49) to Day 92; Digital ECG: Baseline (Day 1) to Day 92
  5. Number of Participants With Abnormal Laboratory Parameters Reported as TEAEsTime frame: Day 1 through 92 days after a single dose of study drug
  6. Number of Abnormal Findings for Ophthalmic Assessment (Ophthalmic Examination and Slit-lamp Examination) for Placebo and Cohorts 4 to 6 at Follow-up VisitTime frame: Follow-up Visit (Day 57)
  7. Intraocular Pressure at Screening for Placebo and Cohorts 4 to 6Time frame: Screening (Day -49)
  8. Intraocular Pressure at Day 29 for Placebo and Cohorts 4 to 6Time frame: Day 29
  9. Intraocular Pressure at Day 92 for Placebo and Cohorts 4 to 6Time frame: Day 92
  10. Number of Participants With Injection Site ReactionsTime frame: Day 1
  11. Visual Analogue Scale (VAS) Pain Score for Site Reaction PainTime frame: Day 1 (within 24 hours after end of infusion)
  12. Number of Participants With Suicidal Ideation and Suicidal Behavior Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Screening (Day -49) through 92 days after a single dose of study drug
  13. Number of Participants With Montreal Cognitive Assessment (MoCA) Total Score at Screening (Day -1)Time frame: Screening (Day -1)
  14. Number of Participants With MoCA Total Score at Day 92Time frame: Day 92

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Dallas, Texas

  • Research Site

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.